Pulmonary hypertension (PH) is severe progressive disease. This study is the first analysis of patient survival in different etiology subgroups after treatment in only one Ukrainian referral center.
Methods: Long-term survival (Kaplan–Meier) was investigated in patients with PH (diagnosed by right heart catheterization) within a prospective registry at a single referral center in Kyiv, Ukraine. Follow-up period was up to 51 (mean 23,6±14,1) months.
In total 281 patients were enrolled (68 [24,2%] with idiopathic pulmonary arterial hypertension (IPAH); 136 [48,4%] with PAH associated with CHD; 15 [5,3%] with PAH associated with CTD; 10 [3,6%] with other PAH; 52 [18,5%] with CTEPH). Survival rates at 1, 2 and 3 year are present in table. At 3 year differences in survival rates between etiologic groups were significant between groups IPAH and CHD (p=0,002), CHD and CTD (p=0,001), CHD and CTEPH (p=0,04), CTD and other PAH (p=0,05).
This is the first Ukrainian single-center PH cohort study results. In spite of irregular and limited specific treatment of PH patients in Ukraine (government drug supporting patient program started since 2016 and only iloprost or sildenafil are available) the survival rates of patients who were treated in referral center are comparable with ones in other European referral centers.
Key words: pulmonary hypertension, etiology, survival, predictors